Research progress of renal damage in rheumatoid arthritis_West China Medical Journal

Authors：

CHEN Xing ^1,2 ,  WEI Meng ²

1. School of Clinical Medicine, Southwest Jiaotong University, Chengdu, Sichuan 610031, P. R. China;
2. Department of Nephrology and Rheumatology, General Hospital of Western Theater Command, Chengdu, Sichuan 610083, P. R. China;

Corresponding?author：

WEI Meng, Email: weimengwm@sina.com

Keywords：

Rheumatoid arthritis; Extra-articular manifestation; Renal damage

DOI：

10.7507/1002-0179.201906137

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases. It mainly involves joints, as well as extra-articular organs. The extra-articular manifestations (EAM) are more common in patients with severe active disease, and the mortality of RA patients with EAM is 2.5 times of RA patients without EAM. Renal damage is rare in EAM, which mainly includes renal damage associated with RA itself, renal amyloidosis, and drug-induced secondary renal damage. In recent years, researches on RA renal damage have gradually increased, and mainly focused on therapy and prognosis. The recent research progress of RA renal damage are summarized in this review.

Citation： CHEN Xing, WEI Meng. Research progress of renal damage in rheumatoid arthritis. West China Medical Journal, 2019, 34(11): 1311-1314. doi: 10.7507/1002-0179.201906137 Copy

1.	Das S, Padhan P. An Overview of the extraarticular involvement in rheumatoid arthritis and its management. J Pharmacol Pharmacother, 2017, 8(3): 81-86.
2.	Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Buchar), 2010, 5(4): 286-291.
3.	Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol, 2013, 25(3): 360-366.
4.	曾彩虹, 劉志紅, 胡偉新, 等. 類風濕性關節炎相關腎損害的臨床病理特征. 腎臟病與透析腎移植雜志, 2008, 17(4): 311-317.
5.	郭嘉隆, 章來曉. 系膜增生性腎小球腎炎. 中國社區醫師, 2003, 19(9): 15-16.
6.	游雪葉, 鐘山. 710 例腎臟穿刺活檢病理與臨床資料分析. 中國衛生標準管理, 2017, 8(24): 126-128.
7.	祖二梅, 閆桂霞, 劉新華. 潑尼松與嗎替麥考酚酯治療系膜增生性 IgA 腎小球腎炎患者的綜合干預護理分析. 安徽醫藥, 2018, 22(6): 1186-1190.
8.	李寧, 林源. 貝那普利對系膜增生性腎小球腎炎大鼠血清和腎臟中 MMP-9/TIMP-1 的影響. 臨床和實驗醫學雜志, 2018, 17(19): 2041-2043.
9.	徐峰, 曾彩虹. 類風濕性關節炎合并膜性腎病和節段壞死性病變. 腎臟病與透析腎移植雜志, 2014, 23(2): 192-196.
10.	Pozdzik A, Brochériou I, David C, et al. Membranous nephropathy and anti-podocytes antibodies: implications for the diagnostic workup and disease management. Biomed Res Int, 2018, 2018: 6281054.
11.	Li J, Liu B, Xue H, et al. miR-217 is a useful diagnostic biomarker and regulates human podocyte cells apoptosis via targeting TNFSF11 in membranous nephropathy. Biomed Res Int, 2017, 2017: 2168767.
12.	Shouno Y, Shimokama T, Sakemi T, et al. Segmental glomerular necrosis as an active index of IgA nephropathy: a study with 100 serial sections of 128 cases. Acta Pathol Jpn, 1993, 43(12): 723-729.
13.	于峰, 趙明輝, 于凈, 等. 局灶節段壞死性腎小球腎炎 (FSNGN) 的臨床和病理特點. 中國醫刊, 2004, 39(4): 35-37.
14.	Stangou M, Papagianni A, Bantis C, et al. Detection of multiple cytokines in the urine of patients with focal necrotising glomerulonephritis may predict short and long term outcome of renal function. Cytokine, 2012, 57(1): 120-126.
15.	徐菲, 梁冰. 腎淀粉樣變性的研究進展. 國際檢驗醫學雜志, 2015, 36(8): 1126-1128.
16.	Courties A, Grateau G, Philippe P, et al. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid, 2015, 22(2): 84-92.
17.	Targońska-St?pniak B, Majdan M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators Inflamm, 2014, 2014: 793628.
18.	Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet, 2017, 389(10086): 2338-2348.
19.	Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet, 2017, 390(10089): 73-84.
20.	Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev, 2014, 13(8): 873-879.
21.	Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant, 2005, 20(7): 1400-1406.
22.	Michel M, Henri P, Vincent FB, et al. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. Joint Bone Spine, 2013, 80(6): 660-663.
23.	Matsuo Y, Mizoguchi F, Kohsaka H, et al. Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis. Rheumatology (Oxford), 2013, 52(7): 1341-1343.
24.	Kim SK, Choe JY. Gender is a risk factor for annual decline in estimated glomerular filtration rate in patients treated with biological DMARDs in rheumatoid arthritis and ankylosing spondylitis: a retrospective observational study. J Korean Med Sci, 2018, 33(30): e188.
25.	杜卉蓮, 秦陸兵, 趙麗華, 等. 胱抑素 C 與尿微量白蛋白肌酐比值對早期繼發性腎損害的臨床研究. 中國地方病防治雜志, 2014, 29(增刊2): 109.
26.	韓智杰. 胱抑素 C 在類風濕關節炎中的變化及意義. 臨床合理用藥雜志, 2016, 9(7): 22-23.
27.	張玉軍. 繼發性腎損害的分子機制及防治藥物的研究進展. 中國醫院藥學雜志, 2013, 33(17): 1431-1434.
28.	Turesson C, Schaid DJ, Weyand CM, et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther, 2005, 7(6): R1386-R1393.
29.	Pawlik A, Paradowska-Gorycka A, Safranow K, et al. SLC22A5 polymorphism associated with risk of extra-articular manifestations in rheumatoid arthritis patients. Reumatologia, 2019, 57(1): 3-7.

1. Das S, Padhan P. An Overview of the extraarticular involvement in rheumatoid arthritis and its management. J Pharmacol Pharmacother, 2017, 8(3): 81-86.
2. Cojocaru M, Cojocaru IM, Silosi I, et al. Extra-articular manifestations in rheumatoid arthritis. Maedica (Buchar), 2010, 5(4): 286-291.
3. Turesson C. Extra-articular rheumatoid arthritis. Curr Opin Rheumatol, 2013, 25(3): 360-366.
4. 曾彩虹, 劉志紅, 胡偉新, 等. 類風濕性關節炎相關腎損害的臨床病理特征. 腎臟病與透析腎移植雜志, 2008, 17(4): 311-317.
5. 郭嘉隆, 章來曉. 系膜增生性腎小球腎炎. 中國社區醫師, 2003, 19(9): 15-16.
6. 游雪葉, 鐘山. 710 例腎臟穿刺活檢病理與臨床資料分析. 中國衛生標準管理, 2017, 8(24): 126-128.
7. 祖二梅, 閆桂霞, 劉新華. 潑尼松與嗎替麥考酚酯治療系膜增生性 IgA 腎小球腎炎患者的綜合干預護理分析. 安徽醫藥, 2018, 22(6): 1186-1190.
8. 李寧, 林源. 貝那普利對系膜增生性腎小球腎炎大鼠血清和腎臟中 MMP-9/TIMP-1 的影響. 臨床和實驗醫學雜志, 2018, 17(19): 2041-2043.
9. 徐峰, 曾彩虹. 類風濕性關節炎合并膜性腎病和節段壞死性病變. 腎臟病與透析腎移植雜志, 2014, 23(2): 192-196.
10. Pozdzik A, Brochériou I, David C, et al. Membranous nephropathy and anti-podocytes antibodies: implications for the diagnostic workup and disease management. Biomed Res Int, 2018, 2018: 6281054.
11. Li J, Liu B, Xue H, et al. miR-217 is a useful diagnostic biomarker and regulates human podocyte cells apoptosis via targeting TNFSF11 in membranous nephropathy. Biomed Res Int, 2017, 2017: 2168767.
12. Shouno Y, Shimokama T, Sakemi T, et al. Segmental glomerular necrosis as an active index of IgA nephropathy: a study with 100 serial sections of 128 cases. Acta Pathol Jpn, 1993, 43(12): 723-729.
13. 于峰, 趙明輝, 于凈, 等. 局灶節段壞死性腎小球腎炎 (FSNGN) 的臨床和病理特點. 中國醫刊, 2004, 39(4): 35-37.
14. Stangou M, Papagianni A, Bantis C, et al. Detection of multiple cytokines in the urine of patients with focal necrotising glomerulonephritis may predict short and long term outcome of renal function. Cytokine, 2012, 57(1): 120-126.
15. 徐菲, 梁冰. 腎淀粉樣變性的研究進展. 國際檢驗醫學雜志, 2015, 36(8): 1126-1128.
16. Courties A, Grateau G, Philippe P, et al. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid, 2015, 22(2): 84-92.
17. Targońska-St?pniak B, Majdan M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators Inflamm, 2014, 2014: 793628.
18. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet, 2017, 389(10086): 2338-2348.
19. Sieper J, Poddubnyy D. Axial spondyloarthritis. Lancet, 2017, 390(10089): 73-84.
20. Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev, 2014, 13(8): 873-879.
21. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant, 2005, 20(7): 1400-1406.
22. Michel M, Henri P, Vincent FB, et al. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. Joint Bone Spine, 2013, 80(6): 660-663.
23. Matsuo Y, Mizoguchi F, Kohsaka H, et al. Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis. Rheumatology (Oxford), 2013, 52(7): 1341-1343.
24. Kim SK, Choe JY. Gender is a risk factor for annual decline in estimated glomerular filtration rate in patients treated with biological DMARDs in rheumatoid arthritis and ankylosing spondylitis: a retrospective observational study. J Korean Med Sci, 2018, 33(30): e188.
25. 杜卉蓮, 秦陸兵, 趙麗華, 等. 胱抑素 C 與尿微量白蛋白肌酐比值對早期繼發性腎損害的臨床研究. 中國地方病防治雜志, 2014, 29(增刊2): 109.
26. 韓智杰. 胱抑素 C 在類風濕關節炎中的變化及意義. 臨床合理用藥雜志, 2016, 9(7): 22-23.
27. 張玉軍. 繼發性腎損害的分子機制及防治藥物的研究進展. 中國醫院藥學雜志, 2013, 33(17): 1431-1434.
28. Turesson C, Schaid DJ, Weyand CM, et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. Arthritis Res Ther, 2005, 7(6): R1386-R1393.
29. Pawlik A, Paradowska-Gorycka A, Safranow K, et al. SLC22A5 polymorphism associated with risk of extra-articular manifestations in rheumatoid arthritis patients. Reumatologia, 2019, 57(1): 3-7.

Previous Article
Analysis of long-term effect on cardiopulmonary resuscitation skills in medical students with different training methods
Next Article
Progress in research on pusher syndrome

West China Medical Journal

Research progress of renal damage in rheumatoid arthritis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content